Hydroxocobalamine Hcl Cf

Hydroxocobalamin chloride, the active ingredient in Hydroxocobalamine Hcl Cf, is a cobalamin (Vitamin B12) presented as an injectable solution for intramuscular and subcutaneous use. It treats vitamin B12 deficiency, pernicious anemia, and cyanide poisoning in patients requiring parenteral therapy.

GNH USA supplies Hydroxocobalamine Hcl Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Hydroxocobalamin chloride is used to correct deficiencies and toxic exposures related to the cobalamin pathway.

Vitamin B12 deficiency: restores normal hematologic parameters and neurological function. Pernicious anemia: provides the necessary cobalamin to correct anemia caused by intrinsic factor deficiency. Cyanide poisoning: binds cyanide ions to form cyanocobalamin, facilitating detoxification and excretion.

Hydroxocobalamin chloride may cause a range of adverse reactions following injection.

Common Side Effects: - Injection site pain or erythema - Mild fever or chills - Headache - Nausea or dizziness

Serious or Rare Side Effects: - Anaphylactic reaction or severe hypersensitivity - Acute hypotension - Stevens‑Johnson syndrome or severe skin reactions - Hemolytic anemia, thrombocytopenia, or acute renal failure

Before initiating therapy, consider patient‑specific factors and monitor for reactions.

Assess baseline B12 status: confirm deficiency before treatment. Monitor for allergic reactions: observe injection site and systemic signs. Use caution in renal impairment: adjust monitoring as needed. Avoid in known hypersensitivity to cobalamin or formulation components. Pregnancy and lactation: safety not established; weigh benefits against risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydroxocobalamin may interact with other agents that affect vitamin B12 metabolism or cause additive toxicity.

Major Interactions (Avoid): - Metformin: may exacerbate B12 deficiency, monitor levels. - Chloramphenicol: combined bone‑marrow suppression risk, use with caution.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may reduce oral B12 absorption, though injection bypasses GI tract; monitor clinical response. - Anticonvulsants (phenytoin, carbamazepine): may increase B12 turnover, watch for deficiency signs. - Nitrous oxide exposure: inactivates cobalamin, consider supplemental dosing.